Differentiated strategies of cerebroprotection in arterial hypertension: focus on proven efficacy
- 00:01:03
cognitive impairment is the first sign of brain damage in hypertension
- 00:03:48
with BP >130/80 the risk of dementia increases by 35%
- 00:15:43
Sartans reduce the risk of dementia by almost 50%
- 00:19:16
Neuroprotection is an integral part of the management of patients with hypertension
- 00:27:54
MEMO study: data on the clinical efficacy of Mexidol Mexidol
Aleksey Ivanovich Kochetkov , PhD, functional diagnostics physician, associate professor at the Department of Therapy and Polymorbid Pathology named after Academician M.S. Vovsi, Federal State Budgetary Educational Institution of Higher Professional Education, Russian Medical Academy of Postgraduate Education, Ministry of Health of the Russian Federation
Announcement:
Associate Professor of the M.S. Vovsi Department of Therapy and Polymorbid Pathology at the Russian Medical Academy of Postgraduate Education (RMANPE) of the Ministry of Health of the Russian Federation by Alexey Ivanovich Kochetkov,. His presentation focuses on modern approaches to protecting the brain in patients with arterial hypertension.
Thanks to this video you will learn:
- Why are cognitive impairments not complaints, but the first and main sign of damage to the brain as a target organ in hypertension?
- What early symptoms (decreased concentration, brain fog) should not be ignored?
- Why do 70–80% of patients with stage 2 hypertension have cognitive impairment?
The video examines in detail the role of vascular risk factors:
- Blood pressure control (especially systolic >130 mmHg);
- Correction of atrial fibrillation, diabetes, dyslipidemia;
- The influence of depression, anxiety and asthenia on cognitive status.
The video also highlights the MIND diet to slow the progression of cognitive impairment and cognitive stimulation, simple yet effective methods for patients.
Pharmacological strategy:
- Antihypertensive therapy: why are sartans, diuretics and calcium antagonists preferable?
- Centrally acting ACE inhibitors (perindopril, ramipril) - their role in protecting the brain;
- Why is antihypertensive therapy alone not enough? Antihypertensive cerebroprotection develops slowly — and cognitive status improvement is needed now.
Key takeaway: Neuroprotection is not an option, but a necessity and an integral part of managing patients with arterial hypertension.
Based on the MEMO study, the effectiveness of the drug Mexidol in patients with chronic cerebral ischemia and hypertension has been proven.
Watch the report to:
- Learn to identify cognitive impairment at early stages;
- Understand how to build a comprehensive patient management strategy;
- Find out why Mexidol is an evidence-based choice.
The video is a must-see for therapists, cardiologists, neurologists and general practitioners.
- 00:01:03
cognitive impairment is the first sign of brain damage in hypertension
- 00:03:48
with BP >130/80 the risk of dementia increases by 35%
- 00:15:43
Sartans reduce the risk of dementia by almost 50%
- 00:19:16
Neuroprotection is an integral part of the management of patients with hypertension
- 00:27:54
MEMO study: data on the clinical efficacy of Mexidol Mexidol